newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - SAB BIOTHERAPEUTICS INC

  • Explicit Guidance:

    • Clinical Data Release: Top-line data from the pivotal Phase 2b "SAVEGUARD" study expected in 2027; data release timeline for Phase 3 "PRIZE" study currently undefined pending enrollment pace but anticipated to follow first patient enrollment in the current quarter.
    • Regulatory Milestones: Anticipates filing a Biologics License Application (BLA) for market registration immediately following positive top-line results from the SAVEGUARD study (estimated 2027).
    • Market Opportunity: Management anticipates a $20 billion total addressable market (TAM) for Type 1 Diabetes (T1D) as a disease-modifying autoimmunity indication, noting current market penetration is in early stages.
  • Business-Segment Outlook:

    • Product Portfolio:
      • SAB-142 (Human Antithymocyte Immunoglobulin): Positioned as a superior second-comer to T-Zield. Expected to demonstrate efficacy in preserving C-peptide (primary endpoint) and improving HbA1c, reducing insulin use, decreasing hypoglycemic events, and improving "time in range" (secondary endpoints) via continuous glucose monitoring.
      • Target Product Profile: Differentiates from competitors with a 2-day dosing regimen (vs. 12-day for T-Zield), redosability for chronic disease management (vs. T-Zield's one-time infusion), and a fully human composition to avoid serum sickness.
    • Study Expansion (PRIZE Study): A Phase 3 investigator-initiated study will expand the eligible patient window from the standard 100 days post-diagnosis to up to two years (Cohort 2: 100–365 days; Cohort 3: 365 days–2 years). Positive results here are expected to expand the commercial label and market access.
    • Enrollment Metrics: PRIZE study targets enrollment of 72 new patients across 7 sites; first patient enrolled in the current quarter.
  • Market and Competitive Outlook:

    • Competitive Landscape: Acknowledges T-Zield's recent FDA approval and its role in educating the medical community on C-peptide preservation. Expects a "strong second-comer advantage" for SAB-142 driven by superior convenience and efficacy.
    • Competitor Performance: Notes T-Zield's Stage 3 first-quarter sales reached approximately $47 million (vs. $25 million plateau in Stage 2), indicating strong market acceptance despite the 12-day dosing burden.
    • Market Share Dynamics: Anticipates capturing significant market share as the industry shifts from "insulin management" to "organ preservation," with SAB-142 positioned to capture patients outside the narrow 100-day window of competitors.
  • Macro / Industry Outlook:

    • Disease Paradigm Shift: Foresees a structural shift in the T1D treatment landscape toward immunomodulation and disease-modifying therapies aimed at preserving endogenous insulin production, moving beyond traditional insulin delivery and glucose monitoring.
    • Commercialization Timeline: The company views the current period as "early days" for the T1D autoimmunity sector, with growing investor and pharma interest following the 2024 approval of T-Zield.
    • Pricing/Reimbursement: While not explicitly stating future pricing, management anticipates that achieving full approval (via secondary endpoints) rather than accelerated approval (C-peptide only) will provide a "massive value inflection point" for a pre-commercial company.
  • Strategic Initiatives:

    • Pivotal Trial Execution: Finalizing enrollment for the SAVEGUARD study this month; trial design modeled after the "TN-19" study (using thymoglobulin historical data) to ensure statistical power for both C-peptide and HbA1c endpoints.
    • Pipeline Expansion: Advancing the PRIZE study to validate treatment efficacy up to two years post-diagnosis, aiming to broaden the label eligibility and address patient/advocate concerns regarding arbitrary time-from-diagnosis restrictions.
    • Regulatory Strategy: Prepared to pursue accelerated approval based on C-peptide preservation alone if secondary endpoints are not met in SAVEGUARD, with a pre-planned strategy to conduct additional trials to satisfy full approval requirements.
  • Risks and Headwinds to Outlook:

    • Trial Uncertainty: While confidence is high based on historical data from thymoglobulin, there is a risk that the study may only hit the primary C-peptide endpoint, necessitating further trials for full approval.
    • Enrollment Variability: Control over the PRIZE study timeline is limited as it is run by academic investigators; enrollment pace could delay data availability.
    • Competitive Headwinds: T-Zield's dominance in establishing the category could initially overshadow SAB-142, though management argues their dosing and redosability advantages will secure adoption.
    • Safety Concerns: Anticipated adverse events include infusion-related reactions, headaches, and Grade 1 CRS (flu-like symptoms with fever), which are expected to be manageable but must be monitored.
  • Management Tone on the Future:

    • Confidence Level: High confidence ("high confidence in our likelihood of success") regarding the ability to hit secondary endpoints (HbA1c) due to the study design mirroring the successful thymoglobulin trials.
    • Strategic Optimism: Expresses strong conviction that SAB-142 offers a "superior product" for preserving insulin production and will "transform what it means to have T1D."
    • Differentiation Focus: Emphasizes a clear competitive moat (2-day vs. 12-day dosing, redosability, human vs. rabbit protein) as the key driver for market adoption.
  • Miscellaneous:

    • Target Patient Profile: Focus on newly diagnosed patients; SAVEGUARD covers patients within the first 100 days of diagnosis, while PRIZE targets those diagnosed up to 2 years prior.
    • Data Measurement: All patients in the SAVEGUARD trial are required to use continuous glucose monitoring to accurately measure "time in range" and insulin use trends.
Company
SAB BIOTHERAPEUTICS INC
Keywords
SAB BIOTHERAPEUTICS INC